ursodeoxycholic acid has been researched along with Fatty Liver, Nonalcoholic in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 49 (75.38) | 24.3611 |
| 2020's | 16 (24.62) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelaziz, AE; Abdelkawy, KS; Ali, AA; Elbarbry, F; Fouda, A; Hussien, M | 1 |
| Boldizhar, OO; Derbak, MA; Ganich, TM; Khramtsova, IO; Lazur, YV | 1 |
| Peng, Y; Qiu, L; Xie, P | 1 |
| Aishima, S; Eguchi, Y; Higurashi, T; Honda, A; Honda, Y; Hosono, K; Hyogo, H; Imajo, K; Iwaki, M; Kage, M; Kasai, Y; Kato, S; Kawaguchi, T; Kawanaka, M; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Oyamada, S; Ozaki, A; Saito, S; Shinoda, S; Sumida, Y; Takahashi, H; Takahashi, K; Tanaka, K; Torimura, T; Usuda, H; Wada, K; Yamamoto, A; Yoneda, M | 1 |
| Guo, H; He, T; Huang, H; Lin, X; Mai, M; Xia, E; Zhang, P | 1 |
| Bellini, R; Biagioli, M; Bordoni, M; Di Giorgio, C; Distrutti, E; Fiorucci, S; Marchianò, S; Monti, MC; Morretta, E; Roselli, R; Urbani, G; Zampella, A | 1 |
| Fujitsuka, N; Iizuka, S; Ishizawa, S; Kaifuchi, N; Kono, T; Nahata, M; Nishi, A; Nishiyama, M; Ohbuchi, K; Shimobori, C; Yamada, C; Yamamoto, M | 1 |
| Breder, VV; Doshchitsin, VL; Dudinskaya, EN; Ershova, EV; Geyvandova, NI; Ivashkin, VT; Kodzoeva, KB; Komshilova, KA; Korochanskaya, NV; Kotovskaya, YV; Maevskaya, MV; Mayorov, AY; Mishina, EE; Nadinskaya, MY; Nikitin, IG; Pogosova, NV; Shamkhalova, MS; Shestakova, MV; Tarzimanova, AI; Tkacheva, ON; Troshina, EA | 1 |
| Bellini, R; Biagioli, M; Bordoni, M; Di Giorgio, C; Distrutti, E; Fiorucci, S; Marchianò, S; Massa, C; Monti, MC; Morretta, E; Roselli, R; Urbani, G; Zampella, A | 1 |
| Blaga, OS; Hechko, MM; Ivachevska, VV; Ivachevskyi, MM; Myhovych, II | 1 |
| Cotrim, HP; Oliveira, CP; Parise, ER; Salgado, ALA; Siqueira, ACG; Stefano, JT | 1 |
| Lee, HW; Lee, JI; Lee, KS | 1 |
| Guo, Y; Wu, P; Wu, X; Xiao, H; Yu, Y; Zhao, J | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Hu, H; Huang, J; Tang, Y; Zhang, W | 1 |
| Arab, JP; Candia, R; Kulkarni, AV; Kumar, P; Padaki, NR; Premkumar, M; Reddy, DN; Sharma, M; Tevethia, HV | 1 |
| Chesnokov, E; Ivashkin, V; Kaibullayeva, J; Khamrabaeva, F; Kodzoeva, K; Konysbekova, A; Maevskaya, M; Nadinskaia, M; Nersesov, A; Pirogova, I; Raissova, A; Zueva, E | 1 |
| Choi, JH; Heo, NY; Hwang, JS; Jeong, SJ; Kim, E; Kim, TO; Lee, J; Oh, EH; Park, J; Park, SH; Park, YE | 1 |
| Bae, JS; Cha, JY; Hahm, KB; Han, YM; Ko, KH; Lee, HJ; Oh, BC; Park, JM | 1 |
| Auer, N; Castro, RE; Herac, M; Marschall, HU; Mueller, M; Rodrigues, CMP; Thorell, A; Trauner, M | 1 |
| Dudanova, OP; Kurbatova, IV; Topchieva, LV | 1 |
| Alohina, LM; Chumak, AA; Gasanov, VA; Gasanova, OV; Kryzhanivska, VV; Nosach, OV; Ovsyannikova, LM; Sarkisova, EO | 1 |
| Aguesse, A; Boursier, J; Chaigneau, J; Coué, M; Croyal, M; Falewée, J; Fizanne, L; Ouguerram, K; Tesse, A | 1 |
| Shetty, A; Syn, WK | 1 |
| Hongguang, J; Jingmo, Y; Liang, L; Lifang, Z; Mingliang, J; Tongjian, L; Xingjie, H; Yun, L | 1 |
| Chen, ZY; Hong, W; Hu, J; Yao, KN; Ye, L; Zhu, XH | 1 |
| Azarbayjani, AF; Gheibi, S; Gouvarchin Ghaleh, HE; Motlagh, BM; Zarei, L | 1 |
| Ivashkin, KV; Ivashkin, VT; Leshchenko, VI; Liusina, EO; Lunkov, VD; Maevskaya, MV; Zozula, VN | 1 |
| Barbakadze, G; Burnadze, K; Jebashvili, M; Khachidze, T; Sulaberidze, G | 1 |
| Biagioli, M; Carino, A; Distrutti, E; Fiorucci, C; Fiorucci, S; Marchianò, S; Monti, MC; Ricci, P; Scarpelli, P; Zampella, A | 1 |
| Boettler, T; Demir, M; Fickert, P; Geier, A; Greinwald, R; Halilbasic, E; Hofmann, WP; Kluwe, J; Kremer, AE; Manns, MP; Petersen, J; Pröls, M; Rainer, F; Schattenberg, JM; Spreda, F; Teuber, G; Trauner, M; Traussnigg, S; Wiegand, J | 1 |
| Chen, YP; Jin, X; Li, YM; Ma, KF; Xiang, Z; Yang, YD; Ye, YF; Zheng, L | 1 |
| Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM | 1 |
| Luzina, EV; Tomina, EA; Zhilina, AA | 1 |
| Arab, JP; Arrese, M; Padilla, O; Pizarro, M; Quintero, P; Riquelme, A; Solís, N | 1 |
| Avalueva, EB; Ivanov, SV; Lapinskiĭ, IV; Orishak, EA; Skazyvaeva, EV; Tkachenko, EI | 1 |
| Cheon, GJ; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, SG; Kim, YD; Kim, YS; Lee, SH | 1 |
| Chang, HY; Choi, J; Kim, JK; Lee, DK; Lee, JI; Lee, KS; Lee, SY | 1 |
| Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS | 1 |
| Baskol, G; Baskol, M; Doğan, S; Gursoy, S; Ozel Coskun, BD; Yagbasan, A; Yucesoy, M; Yurci, A | 1 |
| Claudel, T; Einarsson, C; Fauler, G; Hoesel, B; Jha, P; Koefeler, H; Lackner, C; Marschall, HU; Mueller, M; Stojakovic, T; Thorell, A; Trauner, M | 1 |
| Carr, RM; Reid, AE | 1 |
| Chamulitrat, W; Liebisch, G; Okun, JG; Pathil, A; Schmitz, G; Stremmel, W | 1 |
| Abdel-Latif, HA; Ali, MH; Messiha, BA | 1 |
| Aihara, Y; Douhara, A; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Seki, K; Takaya, H; Takeda, K; Yoshiji, H | 1 |
| Klyarytskaya, IL; Maksymova, EV; Stilidi, EI | 1 |
| Cho, B; Choi, WS; Lee, ES; Lee, JH; Oh, B; Park, SB; Yang, YJ | 1 |
| Ganesh, S; Rustgi, VK | 1 |
| Belavina, LA; Dudanova, OP; Kurbatova, IV; Larina, AA; Topchieva, LV | 1 |
| Alawad, AS; Levy, C | 1 |
| He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY | 1 |
| Claudel, T; Steinacher, D; Trauner, M | 1 |
| Dufour, JF; Haedrich, M | 1 |
| Bastard, JP; Bonnefont-Rousselot, D; de Ledinghen, V; Larrey, D; Mathurin, P; Maynard, M; Oberti, F; Ratziu, V; Renou, C; Rivière, M; Serfaty, L; Sogni, P; Spénard, J; Wartelle-Bladou, C | 1 |
| Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J | 1 |
| Dumortier, J; Guillaud, O; Hervieu, V; Pietu, F; Scoazec, JY; Vallin, M; Walter, T | 1 |
| Chamulitrat, W; Mueller, J; Pathil, A; Stremmel, W; Warth, A | 1 |
| Harrison, SA; Paredes, AH; Torres, DM | 1 |
| Grigor'eva, IN | 2 |
| Li, L; Wang, JY; Wu, SD | 1 |
| Afonso, MB; Borralho, PM; Castro, RE; Cortez-Pinto, H; Ferreira, DM; Machado, MV; Rodrigues, CM | 1 |
| Ratziu, V | 1 |
| Dufour, JF; Liechti, F | 1 |
21 review(s) available for ursodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis.
Topics: Alanine Transaminase; Cholagogues and Choleretics; Humans; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2022 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials.
Topics: Europe; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2020 |
Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Topics: Chenodeoxycholic Acid; Cholestasis; Humans; Liver Cirrhosis, Biliary; Non-alcoholic Fatty Liver Disease; Pharmaceutical Preparations; Ursodeoxycholic Acid | 2021 |
Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Topics: Animals; Carcinoma, Hepatocellular; Drug Design; Fatty Acids, Omega-3; Humans; Immunoglobulins; Liver Cirrhosis; Liver Neoplasms; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Tocotrienols; Ursodeoxycholic Acid | 2017 |
Current treatment options for nonalcoholic fatty liver disease.
Topics: Antioxidants; Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Coffee; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Receptors, Cytoplasmic and Nuclear; Sleep; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2019 |
Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
Topics: Cholagogues and Choleretics; Humans; Hypertension; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Risk Factors; Ursodeoxycholic Acid | 2019 |
The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
Topics: Cholagogues and Choleretics; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid | 2013 |
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Precision Medicine; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E; Weight Loss | 2014 |
[Obesity and diseases of digestive organs].
Topics: Body Mass Index; Cholagogues and Choleretics; Cholelithiasis; Diet Therapy; Endoscopy, Gastrointestinal; Fatty Liver; Gastroesophageal Reflux; Health Behavior; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Risk Factors; Ursodeoxycholic Acid | 2013 |
FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fatty Liver, Alcoholic; Humans; NF-kappa B; Non-alcoholic Fatty Liver Disease; Phosphoenolpyruvate Carboxykinase (ATP); PPAR alpha; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Ursodeoxycholic Acid | 2015 |
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2016 |
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases | 2016 |
Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Bile Acids and Salts; Clinical Trials as Topic; Humans; Ligands; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2017 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibrosis; Hepatocytes; Humans; Hypertriglyceridemia; Insulin Resistance; Kupffer Cells; Liver Cirrhosis; Liver Transplantation; Metformin; Models, Biological; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Ursodeoxycholic Acid; Vitamin E | 2011 |
Nonalcoholic fatty liver disease.
Topics: Antioxidants; Biomarkers; Cholagogues and Choleretics; Diabetes Complications; Fatty Acids, Omega-3; Fatty Liver; Female; Free Radical Scavengers; Humans; Hypoglycemic Agents; Life Style; Middle Aged; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Ursodeoxycholic Acid; Weight Loss | 2012 |
[UDCA in the treatment of nonalcoholic fatty liver disease].
Topics: Adiponectin; Apoptosis; Cholagogues and Choleretics; Fatty Liver; Hepatocytes; Humans; Insulin; Liver X Receptors; NAD; Non-alcoholic Fatty Liver Disease; Orphan Nuclear Receptors; Receptors, G-Protein-Coupled; Ursodeoxycholic Acid | 2011 |
[UDCA in the treatment of nonalcoholic fatty liver disease].
Topics: Cholagogues and Choleretics; Fatty Liver; Glucagon-Like Peptide 1; Humans; Non-alcoholic Fatty Liver Disease; Receptors, G-Protein-Coupled; Ursodeoxycholic Acid | 2011 |
Ursodeoxycholic acid for nonalcoholic steatohepatitis.
Topics: Adult; Animals; Biomarkers; Biopsy; Chi-Square Distribution; Cholagogues and Choleretics; Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Odds Ratio; Treatment Outcome; Ursodeoxycholic Acid | 2012 |
Treatment of NASH with ursodeoxycholic acid: pro.
Topics: Anti-Inflammatory Agents; Cholagogues and Choleretics; Evidence-Based Medicine; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Treatment Outcome; Ursodeoxycholic Acid | 2012 |
15 trial(s) available for ursodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Disease Progression; Egypt; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Single-Blind Method; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2019 |
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Topics: Atherosclerosis; Carotid Intima-Media Thickness; Female; Humans; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2021 |
Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components.
Topics: Alanine Transaminase; Biphenyl Compounds; Hepatitis, Chronic; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2021 |
Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
Topics: Apoptosis; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Humans; Liver; MicroRNAs; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Oxidative Stress; Sweden; Transcription Factor CHOP; Unfolded Protein Response; Ursodeoxycholic Acid | 2018 |
Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
Topics: Cholagogues and Choleretics; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Ursodeoxycholic Acid | 2019 |
COMPARATIVE ANALYSIS OF EFFICIENCY OF URSODEOXYCHOLIC ACID AND COMBINATION OF VITAMIN E AND VITAMIN C IN TREATMENT OF NON-DIABETIC NONALCOHOLIC STEATOHEPATITIS.
Topics: Antioxidants; Ascorbic Acid; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2019 |
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholagogues and Choleretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
[Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Cholagogues and Choleretics; Dioxoles; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis, Alcoholic; Hepatitis, Chronic; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Tertiary Care Centers; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2014 |
Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
Topics: Adolescent; Adult; Aged; Anthropometry; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Biopsy; Carotid Intima-Media Thickness; Cholagogues and Choleretics; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Ursodeoxycholic Acid; Waist Circumference; Young Adult | 2015 |
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Topics: Bile Acids and Salts; Humans; Intra-Abdominal Fat; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Oleic Acid; Receptors, Cytoplasmic and Nuclear; Stearoyl-CoA Desaturase; Ursodeoxycholic Acid | 2015 |
[COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].
Topics: Adult; Aged; Atorvastatin; Female; Humans; Interleukin-6; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid; Vitamin E | 2015 |
Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial.
Topics: Adult; Cholagogues and Choleretics; Double-Blind Method; Fatigue; Female; Follow-Up Studies; Humans; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2016 |
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
Topics: Adult; Blood Glucose; Cholagogues and Choleretics; Dose-Response Relationship, Drug; Fatty Liver; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid | 2011 |
29 other study(ies) available for ursodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Topics: Administration, Oral; Humans; Immunotherapy; Non-alcoholic Fatty Liver Disease; Pulmonary Disease, Chronic Obstructive; Ursodeoxycholic Acid | 2021 |
Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
Topics: Animals; Chitosan; Diet, High-Fat; Exenatide; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Sirtuin 1; Ursodeoxycholic Acid | 2022 |
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study.
Topics: Bile Acids and Salts; Biopsy; Fibrosis; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2022 |
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.
Topics: Animals; Bile Acids and Salts; Humans; Mice; Non-alcoholic Fatty Liver Disease; Receptors, G-Protein-Coupled; Rodentia; Ursodeoxycholic Acid | 2022 |
Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease.
Topics: Amino Acids; Animals; Arachidonic Acids; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Gastrointestinal Microbiome; Japan; Lipids; Liver; Medicine, Traditional; Metabolome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2022 |
[The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
Topics: Adult; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Diabetes Mellitus, Type 2; Glucose; Humans; Inflammation; Lipids; Liver; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2022 |
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
Topics: Animals; Bile Acids and Salts; Liver; Mice; Non-alcoholic Fatty Liver Disease; Receptors, G-Protein-Coupled; Ursodeoxycholic Acid | 2023 |
EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETES.
Topics: Fatty Acids, Omega-3; Humans; Non-alcoholic Fatty Liver Disease; Prediabetic State; Rosuvastatin Calcium; Ursodeoxycholic Acid | 2023 |
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Topics: Adult; Biopsy; Disease Progression; Elasticity Imaging Techniques; Female; Follow-Up Studies; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Predictive Value of Tests; Prognosis; Retrospective Studies; ROC Curve; Ursodeoxycholic Acid | 2019 |
Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Enzyme Activation; Enzyme Activators; Male; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Ursodeoxycholic Acid | 2020 |
Gene TNF Polymorphism -308G>A (rs1800629) and Its Relationship with the Efficiency of Ursodeoxycholic Acid Therapy in Patients with Nonalcoholic Stetohepatitis.
Topics: Alanine Transaminase; Alleles; Aspartate Aminotransferases; Case-Control Studies; Female; Gene Expression; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Interleukin-10; Interleukin-6; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Polymorphism, Single Nucleotide; Protective Agents; Russia; Treatment Outcome; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2017 |
Comparative characteristics of hepatoprotectors used for the treatment of non alcoholic steatohepatitis associated with herpesvirus infection in sufferers of the Chornobyl accident.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amino Acids; Bilirubin; Chernobyl Nuclear Accident; Cholesterol; Cnicus; Emergency Responders; Herpesviridae Infections; Humans; Lipid Metabolism; Lipoproteins, LDL; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Occupational Exposure; Phospholipids; Plant Extracts; Prospective Studies; Protective Agents; Radiation Exposure; Radiation Injuries; Triglycerides; Ursodeoxycholic Acid | 2017 |
Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Cholesterol; Cholic Acids; Diet, Western; Dietary Supplements; Fibrosis; Gallbladder; Hypolipidemic Agents; Liver; Liver Cirrhosis; Male; Mice, Inbred C57BL; NF-kappa B; Nitric Oxide; Non-alcoholic Fatty Liver Disease; Spirulina; Superoxides; Thiobarbituric Acid Reactive Substances; Ursodeoxycholic Acid | 2019 |
Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Topics: Cell Line, Tumor; Cholagogues and Choleretics; Humans; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt; Signal Transduction; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Ursodeoxycholic Acid | 2019 |
Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
Topics: Animals; Antioxidants; Biomarkers; Curcumin; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Ursodeoxycholic Acid | 2019 |
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Topics: Animals; Chenodeoxycholic Acid; Diet; Dysbiosis; Humans; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Signal Transduction; Ursodeoxycholic Acid | 2019 |
Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholic Acid; Gene Expression; Glucagon-Like Peptide 1; Glucose Tolerance Test; Incretins; Liver; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Organic Anion Transporters, Sodium-Dependent; Receptors, Cytoplasmic and Nuclear; Symporters; Triglycerides; Ursodeoxycholic Acid | 2014 |
[Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
Topics: Adult; Cholagogues and Choleretics; Fatty Liver; Female; Humans; Intestinal Mucosa; Intestines; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Russia; Time Factors; Ursodeoxycholic Acid | 2013 |
Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Topics: Animals; Cholagogues and Choleretics; Diet, High-Fat; Drug Synergism; Fatty Acids, Omega-3; Fibrosis; Inflammation; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2014 |
[CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Topics: Adult; Allopurinol; Bile; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Cholesterol; Cholic Acid; Deoxycholic Acid; Drug Therapy, Combination; Duodenoscopy; Female; Fluorobenzenes; Humans; Hyperuricemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Taurocholic Acid; Uric Acid; Ursodeoxycholic Acid | 2014 |
Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Topics: Aldehyde Oxidase; Animals; Arachidonic Acid; Carnitine O-Palmitoyltransferase; Cholagogues and Choleretics; Diet, High-Fat; Disease Models, Animal; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Lipid Metabolism; Liver; Lysophospholipids; Mass Spectrometry; Mice; Mitochondria; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphatidylcholines; PPAR alpha; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcriptome; Ursodeoxycholic Acid | 2015 |
Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Topics: Acetylcysteine; Animals; Antioxidants; Biomarkers; Choline Deficiency; Cytoprotection; Disease Models, Animal; Hypolipidemic Agents; Lipids; Liver; Male; Methionine; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats, Wistar; Resveratrol; Stilbenes; Ursodeoxycholic Acid | 2016 |
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Cytokines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endotoxins; Inflammation Mediators; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4; Ursodeoxycholic Acid | 2016 |
[EFFICIENCY OF URSODEOXYCHOLIC ACID APPLICATION IN NONALCOCHOLIC STEATOHEPATITIS].
Topics: Aged; Alkaline Phosphatase; Caspases; Dose-Response Relationship, Drug; Female; gamma-Glutamyltransferase; Humans; Liver; Liver Circulation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Ultrasonography; Ursodeoxycholic Acid | 2015 |
UDCA for NASH: end of the story?
Topics: Cholagogues and Choleretics; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2011 |
Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Fatty Liver; Humans; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Time Factors; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E; Vitamins; Young Adult | 2012 |
Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Topics: Animals; Biopsy, Needle; Caspase 8; Diet; Disease Models, Animal; Down-Regulation; Fatty Liver; Hepatitis; Immunohistochemistry; Lipid Peroxidation; Lipogenesis; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Random Allocation; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2012 |
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Topics: Animals; Apoptosis; Biopsy; Fatty Liver; Hepatocytes; Humans; Liver; Male; MicroRNAs; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Signal Transduction; Sirtuin 1; Transcription, Genetic; Tumor Suppressor Protein p53; Ursodeoxycholic Acid | 2013 |
Treatment of NASH with ursodeoxycholic acid: cons.
Topics: Anti-Inflammatory Agents; Cholagogues and Choleretics; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2012 |